Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy
Abstract
:1. Introduction
2. Clinical Significance
- In this current study, we investigated the expression of non-coding RNA transcripts in the serum and cerebrospinal fluid of PSP patients compared to healthy controls to identify diagnostic biomarkers.
- RNA-seq identified dysregulated non-coding RNA transcripts and have confirmed with RT-qPCR that four ncRNA that were changed in serum and two ncRNA that were changed in CSF.
- We conclude that ncRNA in biofluids could be used as potential diagnostic biomarkers for PSP.
3. Results
3.1. Small RNA-Seq Shows Dysregulation of Non-Coding RNA in PSP Patients
3.2. Confirmation of ncRNA Dysregulation from RNA-seq Data with RT-qPCR in Serum and CSF
4. Discussion
5. Methods
5.1. Patient Information
5.2. Sample Collection, Preparation, and RNA Extraction
5.3. RNA-Sequencing
5.4. RT-qPCR Confirmation and Analysis
5.5. Bioinformatic Analysis of MicroRNA Targets
5.6. Statistical Analysis
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
References
- Coyle-Gilchrist, I.T.; Dick, K.M.; Patterson, K.; Vazquez Rodriquez, P.; Wehmann, E.; Wilcox, A.; Lansdall, C.J.; Dawson, K.E.; Wiggins, J.; Mead, S.; et al. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes. Neurology 2016, 86, 1736–1743. [Google Scholar] [CrossRef] [Green Version]
- Takigawa, H.; Kitayama, M.; Wada-Isoe, K.; Kowa, H.; Nakashima, K. Prevalence of progressive supranuclear palsy in Yonago: Change throughout a decade. Brain Behav. 2016, 6, e00557. [Google Scholar] [CrossRef]
- Litvan, I.; Agid, Y.; Calne, D.; Campbell, G.; Dubois, B.; Duvoisin, R.C.; Goetz, C.G.; Golbe, L.I.; Grafman, J.; Growdon, J.H.; et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology 1996, 47, 1–9. [Google Scholar] [CrossRef]
- Hoglinger, G.U.; Respondek, G.; Stamelou, M.; Kurz, C.; Josephs, K.A.; Lang, A.E.; Mollenhauer, B.; Muller, U.; Nilsson, C.; Whitwell, J.L.; et al. Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria. Mov. Disord. 2017, 32, 853–864. [Google Scholar] [CrossRef]
- Respondek, G.; Roeber, S.; Kretzschmar, H.; Troakes, C.; Al-Sarraj, S.; Gelpi, E.; Gaig, C.; Chiu, W.Z.; van Swieten, J.C.; Oertel, W.H.; et al. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov. Disord. 2013, 28, 504–509. [Google Scholar] [CrossRef]
- Jabbari, E.; Holland, N.; Chelban, V.; Jones, P.S.; Lamb, R.; Rawlinson, C.; Guo, T.; Costantini, A.A.; Tan, M.M.X.; Heslegrave, A.J.; et al. Diagnosis Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Syndrome. JAMA Neurol. 2020, 77, 377–387. [Google Scholar] [CrossRef]
- Bensimon, G.; Ludolph, A.; Agid, Y.; Vidailhet, M.; Payan, C.; Leigh, P.N.; Group, N.S. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: The NNIPPS study. Brain 2009, 132, 156–171. [Google Scholar] [CrossRef]
- Boxer, A.L.; Yu, J.T.; Golbe, L.I.; Litvan, I.; Lang, A.E.; Hoglinger, G.U. Advances in progressive supranuclear palsy: New diagnostic criteria, biomarkers, and therapeutic approaches. Lancet Neurol. 2017, 16, 552–563. [Google Scholar] [CrossRef] [Green Version]
- Jabbari, E.; Zetterberg, H.; Morris, H.R. Tracking and predicting disease progression in progressive supranuclear palsy: CSF and blood biomarkers. J. Neurol. Neurosurg. Psychiatry 2017, 88, 883–888. [Google Scholar] [CrossRef]
- Santiago, J.A.; Potashkin, J.A. A network approach to diagnostic biomarkers in progressive supranuclear palsy. Mov. Disord. 2014, 29, 550–555. [Google Scholar] [CrossRef]
- Bacioglu, M.; Maia, L.F.; Preische, O.; Schelle, J.; Apel, A.; Kaeser, S.A.; Schweighauser, M.; Eninger, T.; Lambert, M.; Pilotto, A.; et al. Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases. Neuron 2016, 91, 56–66. [Google Scholar] [CrossRef] [Green Version]
- Wagshal, D.; Sankaranarayanan, S.; Guss, V.; Hall, T.; Berisha, F.; Lobach, I.; Karydas, A.; Voltarelli, L.; Scherling, C.; Heuer, H.; et al. Divergent CSF tau alterations in two common tauopathies: Alzheimer’s disease and progressive supranuclear palsy. J. Neurol. Neurosurg. Psychiatry 2015, 86, 244–250. [Google Scholar] [CrossRef]
- Chen, X.; Ba, Y.; Ma, L.; Cai, X.; Yin, Y.; Wang, K.; Guo, J.; Zhang, Y.; Chen, J.; Guo, X.; et al. Characterization of microRNAs in serum: A novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18, 997–1006. [Google Scholar] [CrossRef] [Green Version]
- Jin, X.F.; Wu, N.; Wang, L.; Li, J. Circulating microRNAs: A novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases. Cell. Mol. Neurobiol. 2013, 33, 601–613. [Google Scholar] [CrossRef]
- Khoo, S.K.; Petillo, D.; Kang, U.J.; Resau, J.H.; Berryhill, B.; Linder, J.; Forsgren, L.; Neuman, L.A.; Tan, A.C. Plasma-based circulating MicroRNA biomarkers for Parkinson’s disease. J. Parkinsons Dis. 2012, 2, 321–331. [Google Scholar] [CrossRef] [Green Version]
- Tatura, R.; Buchholz, M.; Dickson, D.W.; van Swieten, J.; McLean, C.; Hoglinger, G.; Muller, U. microRNA profiling: Increased expression of miR-147a and miR-518e in progressive supranuclear palsy (PSP). Neurogenetics 2016, 17, 165–171. [Google Scholar] [CrossRef]
- Smith, P.Y.; Delay, C.; Girard, J.; Papon, M.A.; Planel, E.; Sergeant, N.; Buee, L.; Hebert, S.S. MicroRNA-132 loss is associated with tau exon 10 inclusion in progressive supranuclear palsy. Hum. Mol. Genet. 2011, 20, 4016–4024. [Google Scholar] [CrossRef] [Green Version]
- Joilin, G.; Gray, E.; Thompson, A.G.; Bobeva, Y.; Talbot, K.; Weishaupt, J.; Ludolph, A.; Malaspina, A.; Leigh, P.N.; Newbury, S.F.; et al. Identification of a potential non-coding RNA biomarker signature for amyotrophic lateral sclerosis. Brain Commun. 2020, 2, fcaa053. [Google Scholar] [CrossRef]
- Waller, R.; Goodall, E.F.; Milo, M.; Cooper-Knock, J.; Da Costa, M.; Hobson, E.; Kazoka, M.; Wollff, H.; Heath, P.R.; Shaw, P.J.; et al. Serum miRNAs miR-206, 143-3p and 374b-5p as potential biomarkers for amyotrophic lateral sclerosis (ALS). Neurobiol. Aging 2017, 55, 123–131. [Google Scholar] [CrossRef]
- Toivonen, J.M.; Manzano, R.; Olivan, S.; Zaragoza, P.; Garcia-Redondo, A.; Osta, R. MicroRNA-206: A potential circulating biomarker candidate for amyotrophic lateral sclerosis. PLoS ONE 2014, 9, e89065. [Google Scholar] [CrossRef]
- Williams, A.H.; Valdez, G.; Moresi, V.; Qi, X.; McAnally, J.; Elliott, J.L.; Bassel-Duby, R.; Sanes, J.R.; Olson, E.N. MicroRNA-206 delays ALS progression and promotes regeneration of neuromuscular synapses in mice. Science 2009, 326, 1549–1554. [Google Scholar] [CrossRef] [Green Version]
- Bruneteau, G.; Simonet, T.; Bauche, S.; Mandjee, N.; Malfatti, E.; Girard, E.; Tanguy, M.L.; Behin, A.; Khiami, F.; Sariali, E.; et al. Muscle histone deacetylase 4 upregulation in amyotrophic lateral sclerosis: Potential role in reinnervation ability and disease progression. Brain 2013, 136, 2359–2368. [Google Scholar] [CrossRef]
- Ramaswamy, P.; Christopher, R.; Pal, P.K.; Yadav, R. MicroRNAs to differentiate Parkinsonian disorders: Advances in biomarkers and therapeutics. J. Neurol. Sci. 2018, 394, 26–37. [Google Scholar] [CrossRef]
- Umu, S.U.; Langseth, H.; Bucher-Johannessen, C.; Fromm, B.; Keller, A.; Meese, E.; Lauritzen, M.; Leithaug, M.; Lyle, R.; Rounge, T.B. A comprehensive profile of circulating RNAs in human serum. RNA Biol. 2018, 15, 242–250. [Google Scholar] [CrossRef] [Green Version]
- Iliev, R.; Fedorko, M.; Machackova, T.; Mlcochova, H.; Svoboda, M.; Pacik, D.; Dolezel, J.; Stanik, M.; Slaby, O. Expression Levels of PIWI-interacting RNA, piR-823, Are Deregulated in Tumor Tissue, Blood Serum and Urine of Patients with Renal Cell Carcinoma. Anticancer Res. 2016, 36, 6419–6423. [Google Scholar] [CrossRef] [Green Version]
- Lopez, J.P.; Diallo, A.; Cruceanu, C.; Fiori, L.M.; Laboissiere, S.; Guillet, I.; Fontaine, J.; Ragoussis, J.; Benes, V.; Turecki, G.; et al. Biomarker discovery: Quantification of microRNAs and other small non-coding RNAs using next generation sequencing. BMC Med. Genom. 2015, 8, 35. [Google Scholar] [CrossRef] [Green Version]
- Joilin, G.; Gray, E.; Thompson, A.G.; Talbot, K.; Leigh, P.N.; Newbury, S.F.; Turner, M.R.; Hafezparast, M. Profiling non-coding RNA expression in cerebrospinal fluid of amyotrophic lateral sclerosis patients. Ann. Med. 2022, 54, 3069–3078. [Google Scholar] [CrossRef]
- Lipps, C.; Northe, P.; Figueiredo, R.; Rohde, M.; Brahmer, A.; Kramer-Albers, E.M.; Liebetrau, C.; Wiedenroth, C.B.; Mayer, E.; Kriechbaum, S.D.; et al. Non-Invasive Approach for Evaluation of Pulmonary Hypertension Using Extracellular Vesicle-Associated Small Non-Coding RNA. Biomolecules 2019, 9, 666. [Google Scholar] [CrossRef] [Green Version]
- Tosar, J.P.; Rovira, C.; Cayota, A. Non-coding RNA fragments account for the majority of annotated piRNAs expressed in somatic non-gonadal tissues. Commun. Biol. 2018, 1, 2. [Google Scholar] [CrossRef] [Green Version]
- Yamasaki, S.; Ivanov, P.; Hu, G.F.; Anderson, P. Angiogenin cleaves tRNA and promotes stress-induced translational repression. J. Cell Biol. 2009, 185, 35–42. [Google Scholar] [CrossRef]
- Emara, M.M.; Ivanov, P.; Hickman, T.; Dawra, N.; Tisdale, S.; Kedersha, N.; Hu, G.F.; Anderson, P. Angiogenin-induced tRNA-derived stress-induced RNAs promote stress-induced stress granule assembly. J. Biol. Chem. 2010, 285, 10959–10968. [Google Scholar] [CrossRef] [Green Version]
- Hogg, M.C.; Rayner, M.; Susdalzew, S.; Monsefi, N.; Crivello, M.; Woods, I.; Resler, A.; Blackbourn, L.; Fabbrizio, P.; Trolese, M.C.; et al. 5’ValCAC tRNA fragment generated as part of a protective angiogenin response provides prognostic value in amyotrophic lateral sclerosis. Brain Commun. 2020, 2, fcaa138. [Google Scholar] [CrossRef]
- Waller, R.; Wyles, M.; Heath, P.R.; Kazoka, M.; Wollff, H.; Shaw, P.J.; Kirby, J. Small RNA Sequencing of Sporadic Amyotrophic Lateral Sclerosis Cerebrospinal Fluid Reveals Differentially Expressed miRNAs Related to Neural and Glial Activity. Front. Neurosci. 2017, 11, 731. [Google Scholar] [CrossRef]
- Coenen-Stass, A.M.L.; Magen, I.; Brooks, T.; Ben-Dov, I.Z.; Greensmith, L.; Hornstein, E.; Fratta, P. Evaluation of methodologies for microRNA biomarker detection by next generation sequencing. RNA Biol. 2018, 15, 1133–1145. [Google Scholar] [CrossRef]
- Wong, R.K.Y.; MacMahon, M.; Woodside, J.V.; Simpson, D.A. A comparison of RNA extraction and sequencing protocols for detection of small RNAs in plasma. BMC Genom. 2019, 20, 446. [Google Scholar] [CrossRef] [Green Version]
- Chen, L.; Yang, J.; Lu, J.; Cao, S.; Zhao, Q.; Yu, Z. Identification of aberrant circulating miRNAs in Parkinson’s disease plasma samples. Brain Behav. 2018, 8, e00941. [Google Scholar] [CrossRef]
- Ramaswamy, P.; Christopher, R.; Kumar Pal, P.; Debnath, M.; Yadav, R. Plasma microRNAs as a Potential Biomarker for Identification of Progressive Supranuclear Palsy. Diagnostics 2022, 12, 1204. [Google Scholar] [CrossRef]
- Nonaka, W.; Takata, T.; Iwama, H.; Komatsubara, S.; Kobara, H.; Kamada, M.; Deguchi, K.; Touge, T.; Miyamoto, O.; Nakamura, T.; et al. A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy. Mol. Med. Rep. 2022, 25, 88. [Google Scholar] [CrossRef]
- Joilin, G.; Leigh, P.N.; Newbury, S.F.; Hafezparast, M. An Overview of MicroRNAs as Biomarkers of ALS. Front. Neurol. 2019, 10, 186. [Google Scholar] [CrossRef] [Green Version]
- Lippi, G.; Salvagno, G.L.; Montagnana, M.; Brocco, G.; Guidi, G.C. Influence of hemolysis on routine clinical chemistry testing. Clin. Chem. Lab. Med. 2006, 44, 311–316. [Google Scholar] [CrossRef]
- Love, M.I.; Huber, W.; Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014, 15, 550. [Google Scholar] [CrossRef] [Green Version]
- Andersen, C.L.; Jensen, J.L.; Orntoft, T.F. Normalization of real-time quantitative reverse transcription-PCR data: A model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004, 64, 5245–5250. [Google Scholar] [CrossRef] [Green Version]
- Vlachos, I.S.; Zagganas, K.; Paraskevopoulou, M.D.; Georgakilas, G.; Karagkouni, D.; Vergoulis, T.; Dalamagas, T.; Hatzigeorgiou, A.G. DIANA-miRPath v3.0: Deciphering microRNA function with experimental support. Nucleic Acids Res. 2015, 43, W460–W466. [Google Scholar] [CrossRef]
DZNE Biobank | PROSPECT | |||
---|---|---|---|---|
Healthy Controls | Possible PSP | Probable PSP | Possible PSP | |
Number of Patients | 20 | 6 | 14 | 11 |
Sex (M/F) | 9/11 | 6/0 | 10/4 | 9/2 |
Average age at sampling (year) | 64.2 (30–79) | 69.8 (64–75) | 72.4 (66–82) | 69.5 (59–81) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Simoes, F.A.; Joilin, G.; Peters, O.; Schneider, L.-S.; Priller, J.; Spruth, E.J.; Vogt, I.; Kimmich, O.; Spottke, A.; Hoffmann, D.C.; et al. Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy. Int. J. Mol. Sci. 2022, 23, 14554. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232314554
Simoes FA, Joilin G, Peters O, Schneider L-S, Priller J, Spruth EJ, Vogt I, Kimmich O, Spottke A, Hoffmann DC, et al. Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy. International Journal of Molecular Sciences. 2022; 23(23):14554. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232314554
Chicago/Turabian StyleSimoes, Fabio A., Greig Joilin, Oliver Peters, Luisa-Sophie Schneider, Josef Priller, Eike Jakob Spruth, Ina Vogt, Okka Kimmich, Annika Spottke, Daniel C. Hoffmann, and et al. 2022. "Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy" International Journal of Molecular Sciences 23, no. 23: 14554. https://0-doi-org.brum.beds.ac.uk/10.3390/ijms232314554